{"id":"https://openalex.org/W2296976918","doi":null,"title":"Overview of antidepressants currently used to treat anxiety disorders.","display_name":"Overview of antidepressants currently used to treat anxiety disorders.","publication_year":1999,"publication_date":"1999-01-01","ids":{"openalex":"https://openalex.org/W2296976918","mag":"2296976918","pmid":"https://pubmed.ncbi.nlm.nih.gov/10634351"},"language":"en","primary_location":{"id":"pmid:10634351","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10634351","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112066093","display_name":"John P. Feighner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"J P Feighner","raw_affiliation_strings":["Feighner Research Institute, San Diego, Calif 92121, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Feighner Research Institute, San Diego, Calif 92121, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5112066093"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.4522,"has_fulltext":false,"cited_by_count":74,"citation_normalized_percentile":{"value":0.9509182,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"60 Suppl 22","issue":null,"first_page":"18","last_page":"22"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9398999810218811,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9398999810218811,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.05689999833703041,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13118","display_name":"Psychological Treatments and Disorders","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antidepressants","display_name":"antidepressants","score":0.9879999756813049},{"id":"https://openalex.org/keywords/anxiety-disorders","display_name":"anxiety disorders","score":0.9990000128746033},{"id":"https://openalex.org/keywords/depression","display_name":"depression","score":0.6809999942779541},{"id":"https://openalex.org/keywords/tricyclic-antidepressants","display_name":"tricyclic antidepressants","score":0.9800000190734863},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9539999961853027},{"id":"https://openalex.org/keywords/imipramine","display_name":"imipramine","score":0.9290000200271606},{"id":"https://openalex.org/keywords/amitriptyline","display_name":"amitriptyline","score":0.9980000257492065},{"id":"https://openalex.org/keywords/panic-disorder","display_name":"panic disorder","score":0.8610000014305115},{"id":"https://openalex.org/keywords/obsessive-compulsive-disorder","display_name":"obsessive-compulsive disorder","score":1.0},{"id":"https://openalex.org/keywords/generalized-anxiety-disorder","display_name":"generalized anxiety disorder","score":0.9890000224113464},{"id":"https://openalex.org/keywords/mirtazapine","display_name":"mirtazapine","score":0.9950000047683716},{"id":"https://openalex.org/keywords/nefazodone","display_name":"nefazodone","score":1.0},{"id":"https://openalex.org/keywords/venlafaxine","display_name":"venlafaxine","score":0.9739999771118164},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6150000095367432}],"concepts":[{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.7317560911178589},{"id":"https://openalex.org/C2777529043","wikidata":"https://www.wikidata.org/wiki/Q741713","display_name":"Panic disorder","level":3,"score":0.7088499069213867},{"id":"https://openalex.org/C2776466888","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine","level":4,"score":0.6423741579055786},{"id":"https://openalex.org/C2781068410","wikidata":"https://www.wikidata.org/wiki/Q421930","display_name":"Mirtazapine","level":4,"score":0.5948468446731567},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.5471372604370117},{"id":"https://openalex.org/C2779419675","wikidata":"https://www.wikidata.org/wiki/Q416632","display_name":"Nefazodone","level":5,"score":0.5402261018753052},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5395843386650085},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5314447283744812},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5277676582336426},{"id":"https://openalex.org/C2776317618","wikidata":"https://www.wikidata.org/wiki/Q544006","display_name":"Anxiety disorder","level":3,"score":0.49900174140930176},{"id":"https://openalex.org/C2779911313","wikidata":"https://www.wikidata.org/wiki/Q845224","display_name":"Generalized anxiety disorder","level":3,"score":0.48743870854377747},{"id":"https://openalex.org/C184117892","wikidata":"https://www.wikidata.org/wiki/Q2075049","display_name":"Neuropsychopharmacology","level":2,"score":0.4430925250053406},{"id":"https://openalex.org/C2781081902","wikidata":"https://www.wikidata.org/wiki/Q3539074","display_name":"Tricyclic","level":2,"score":0.4219758212566376},{"id":"https://openalex.org/C2777765862","wikidata":"https://www.wikidata.org/wiki/Q62903","display_name":"Anxiolytic","level":3,"score":0.4200409948825836},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33463066816329956},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3259373903274536},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.22249451279640198},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.19260162115097046},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.16685950756072998},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.15596958994865417},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069470","descriptor_name":"Venlafaxine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000929","descriptor_name":"Antidepressive Agents, Tricyclic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008996","descriptor_name":"Monoamine Oxidase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015897","descriptor_name":"Comorbidity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:10634351","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10634351","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Journal Article"},{"id":"mag:2296976918","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10634351","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2062293205","https://openalex.org/W2010500572","https://openalex.org/W2135770369","https://openalex.org/W4312862561","https://openalex.org/W2101740291","https://openalex.org/W2093837438","https://openalex.org/W7028956000","https://openalex.org/W2043746513","https://openalex.org/W863574469","https://openalex.org/W2013876942"],"abstract_inverted_index":{"The":[0],"syndromes":[1],"of":[2,29,130,142],"anxiety":[3,38,61,111,131],"and":[4,39,54,74,88,101,119,136],"depression":[5],"may":[6,15,122],"reflect":[7,19],"separate":[8],"disorders":[9,132],"with":[10,21,47,133],"overlapping":[11],"symptoms.":[12],"They":[13],"also":[14],"be":[16],"comorbid":[17,40],"or":[18],"illnesses":[20],"similar":[22,79],"underlying":[23],"pathophysiology":[24],"based":[25],"upon":[26],"a":[27],"spectrum":[28,129],"central":[30],"nervous":[31],"system":[32],"dysfunction.":[33],"Antidepressants":[34],"effectively":[35],"treat":[36],"both":[37],"anxiety-depression.":[41],"Tertiary":[42],"tricyclic":[43],"antidepressant":[44],"agents":[45],"(TCAs)":[46],"dual":[48],"serotonergic-noradrenergic":[49],"effects,":[50],"such":[51,108,115],"as":[52,109,116],"imipramine":[53],"amitriptyline,":[55],"appear":[56],"consistently":[57],"effective":[58,70],"across":[59,126],"the":[60,127,134,140],"disorders.":[62],"Selective":[63],"serotonin":[64],"reuptake":[65],"inhibitors":[66],"(SSRIs)":[67],"are":[68,78,85,96,104,139],"particularly":[69],"in":[71,80,106],"panic":[72],"disorder":[73],"obsessive-compulsive":[75],"disorder.":[76,112],"SSRIs":[77],"efficacy":[81,102],"to":[82,99],"TCAs":[83],"but":[84],"more":[86],"tolerable":[87],"cause":[89],"fewer":[90],"serious":[91],"adverse":[92],"events.":[93],"However,":[94],"they":[95],"relatively":[97],"slow":[98],"act,":[100],"data":[103],"limited":[105],"states":[107],"generalized":[110],"Newer":[113],"antidepressants,":[114],"mirtazapine,":[117],"nefazodone,":[118],"venlafaxine":[120],"XR,":[121],"provide":[123],"some":[124],"benefits":[125],"broad":[128],"safety":[135],"tolerability":[137],"that":[138],"hallmarks":[141],"third":[143],"generation":[144],"antidepressants.":[145]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}